ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

ClinicalTrials.gov ID: NCT04991116

Public ClinicalTrials.gov record NCT04991116. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 12:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis.

Study identification

NCT ID
NCT04991116
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Enrollment
529 participants

Conditions and interventions

Interventions

  • TILD sub-cutaneous (SC) injection Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 29, 2022
Primary completion
Nov 30, 2028
Completion
Mar 31, 2029
Last update posted
Mar 4, 2026

2022 – 2029

United States locations

U.S. sites
41
U.S. states
18
U.S. cities
39
Facility City State ZIP Site status
Sunpharma site no 50 Dothan Alabama 36305
Sunpharma site no 80 Gilbert Arizona 85297
Sunpharma site no 65 Mesa Arizona 85210
Sunpharma site no 105 Phoenix Arizona 85032
Sunpharma site no. 30 Covina California 91722
Sunpharma site no 110 Encino California 91436
Sunpharma site no. 17 Fountain Valley California 92708
Sunpharma site no. 15 Thousand Oaks California 91320
Sunpharma site no 113 Avon Park Florida 33825
Sunpharma site no. 21 Clearwater Florida 33765
Sunpharma site no. 02 Hialeah Florida 33016
Sunpharma site no 71 Kissimmee Florida 34744
Sunpharma site no 107 Margate Florida 33063
Sunpharma site no. 05 New Port Richey Florida 34652
Sunpharma site no 32 Ocoee Florida 34751
SunPharma Site no 22 Tamarac Florida 33321
Sunpharma site no 52 Gainesville Georgia 30501
Sunpharma site no 51 Orland Park Illinois 60467
Sunpharma site no 49 Schaumburg Illinois 60195
Sunpharma site no 47 Skokie Illinois 60076
Sunpharma site no. 20 Wichita Kansas 67207
Sunpharma site no. 14 Springfield Missouri 65807
Sunpharma site no 104 St Louis Missouri 63119
Sunpharma site no 48 Kalispell Montana 59901
Sunpharma Site no 27 Lincoln Nebraska 68516
Sunpharma site no 33 Voorhees Township New Jersey 08043
Sunpharma site no 34 Charlotte North Carolina 28204
Sunpharma site no 111 Leland North Carolina 28451
Sunpharma site no 53 Wilmington North Carolina 28401
Sunpharma site no 35 Minot North Dakota 58701
Sunpharma site no. 11 Middleburg Heights Ohio 44130
Sunpharma site no 31 Greenville South Carolina 29601
Sunpharma site no. 08 Baytown Texas 77521
Sunpharma site no. 13 Baytown Texas 77521
Sunpharma Site no 28 Lubbock Texas 79410
Sunpharma site no 109 Mesquite Texas 75150
Sunpharma site no. 03 San Antonio Texas 78229
Sunpharma site no. 16 San Antonio Texas 78229
Sunpharma site no. 01 Tomball Texas 77375
Sunpharma site no 96 Salt Lake City Utah 84132
Sunpharma site no 66 Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04991116, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 4, 2026 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04991116 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →